Status:
COMPLETED
The Effect of TASH in Patients With HOCM
Lead Sponsor:
Steen Hvitfeldt Poulsen
Conditions:
Hypertrophic Obstructive Cardiomyopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To examine patients with hypertrophic obstructive cardiomyopathy (HOCM) before and after septal alcohol ablation, to investigate the effect of the treatment in regards to changes in myocardial functio...
Detailed Description
Patients with HOCM who develop symptoms of heart failure are treated initially with non-vasodilating ß-blockers or verapamil to decrease myocardial contractility and heart rate. A substantial part of ...
Eligibility Criteria
Inclusion
- Left ventricular wall thickness ≥ 15 mm in one or more myocardial segments that is not explained by loading conditions
- LVOT gradients ≥ 30 mmHg at rest and/or ≥ 50 mmHg at Valsalva's maneuver or exercise
- NYHA ≥ III
Exclusion
- \< 18 years
- Fertile women who do not use anti-contraceptives
- Pregnancy
- Patients are allowed to have a pacemaker (eg. an implantable cardioverter defibrillator (ICD)) but cannot be pace-dependent
- Amiodarone treatment
- Persistent or permanent atrial fibrillation/flutter
- Previous SRT
- Alcohol or drug abuse
- Significant co-morbidity (judged by the investigator)
- Patients who cannot give valid consent (e.g. mental illness or dementia) or who do not understand Danish.
Key Trial Info
Start Date :
May 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04066777
Start Date
May 29 2019
End Date
October 1 2023
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital, Department of Cardiology
Aarhus N, Danmark, Denmark, 8200